Centene Corporation: Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Centene Corporation is a leading provider of government-sponsored healthcare, serving over 28.6 million members through Medicaid, Medicare, and Commercial Marketplace programs. The company operates in four segments: Medicaid, Medicare, Commercial, and Other. The reporting period reflects the ongoing impact of Medicaid redeterminations following the end of the public health emergency, strategic divestitures of international assets, and growth in the Commercial Marketplace segment.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Total Revenues | $42.0 billion | $38.0 billion | $122.3 billion | $114.5 billion |
| Premium & Service Revenues | $36.9 billion | $35.0 billion | $109.2 billion | $104.8 billion |
| Net Earnings (GAAP) | $713 million | $469 million | $3.0 billion | $2.7 billion |
| Diluted EPS (GAAP) | $1.36 | $0.87 | $5.69 | $4.85 |
| Adjusted Diluted EPS | $1.62 | $2.00 | $6.31 | $6.21 |
| Health Benefits Ratio (HBR) | 89.2% | 87.0% | 87.9% | 87.0% |
| SG&A Expense Ratio | 8.3% | 8.7% | 8.4% | 8.7% |
| Cash & Equivalents | $14.6 billion | $17.2 billion | $14.6 billion | $18.5 billion |
| Total Debt | $17.6 billion | $17.8 billion | $17.6 billion | $17.8 billion |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 10% year-over-year in Q3, driven by Medicaid rate increases, a 22% membership growth in the Commercial Marketplace, and higher premium tax revenues. This was partially offset by lower Medicaid membership due to redeterminations.
- Profitability: GAAP net earnings rose 52% to $713 million, primarily due to a lack of significant impairment charges in 2024 compared to $440 million in impairments recorded in Q3 2023 (related to Circle Health and Operose Health divestitures).
- Margin Pressure: The Health Benefits Ratio (HBR) increased to 89.2% from 87.0%, driven by higher acuity in Medicaid post-redetermination and the impact of lower Medicare Star ratings on revenue.
- Segment Performance:
- Commercial: Revenues surged 35% and gross margin increased 27% due to Marketplace expansion and improved product design.
- Medicaid: Gross margin decreased 27% due to membership declines and higher acuity.
- Medicare: Gross margin decreased 30% due to lower Medicare Advantage revenue from Star rating impacts, despite a 49% increase in Prescription Drug Plan (PDP) membership.
- Divestitures: The company completed the sale of Collaborative Health Systems in October 2024 and previously divested Circle Health and Operose Health, reducing the "Other" segment's contribution.
Guidance, Outlook, and Risks
- Medicaid Redeterminations: Management anticipates that remaining membership reductions from Medicaid redeterminations will be limited as most states have substantially completed the process by October 2024. The focus is now on matching rates to acuity.
- Medicare Outlook: The company expects the 2025 Medicare Advantage plan year to operate at a loss driven by Star ratings and intends to record a premium deficiency reserve in Q4 2024. However, 46% of Medicare Advantage membership is now in plans rated 3.5 stars or higher, up from 23% the prior year.
- Capital Allocation: The company continues an aggressive stock repurchase program, with $3.2 billion remaining under the $10 billion authorization. They repurchased $1.2 billion of stock in Q3 2024.
- Liquidity: The company maintains a strong liquidity position with $14.6 billion in cash and equivalents and no borrowings outstanding under its Revolving Credit Facility. It expects available resources to be sufficient for operations for at least 12 months.
- Risks: Key risks include the outcome of Medicaid contract protests, potential further declines in Medicare Star ratings, regulatory changes to healthcare programs, and the impact of inflation on medical costs.
Investor Verification Checklist
- Medicaid Acuity vs. Rates: Verify the timeline and success of state negotiations to adjust Medicaid rates to reflect the higher acuity of the remaining member base post-redetermination.
- Medicare Star Ratings: Monitor the finalization of 2025 Star Ratings and the specific impact of the TTY measure appeal on revenue projections.
- Premium Deficiency Reserves: Confirm the magnitude of the expected premium deficiency reserve for 2025 Medicare Advantage in the upcoming Q4 filing.
- Commercial Growth Sustainability: Assess whether the 22% growth in Marketplace membership is sustainable given the competitive landscape and potential policy changes.
- Divestiture Proceeds: Track the final accounting of the Collaborative Health Systems sale and any contingent consideration adjustments.